WallStSmart

Canopy Growth Corp (CGC)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 1039% more annual revenue ($3.17B vs $278.39M). UTHR leads profitability with a 40.6% profit margin vs -117.3%. UTHR earns a higher WallStSmart Score of 57/100 (C).

CGC

Avoid

30

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: -17.32

UTHR

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 9.0Value: 5.3Quality: 7.8
Piotroski: 5/9Altman Z: 8.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CGC.

UTHRUndervalued (+2.5%)

Margin of Safety

+2.5%

Fair Value

$487.82

Current Price

$549.87

$62.05 discount

UndervaluedFair: $487.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CGC1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

UTHR4 strengths · Avg: 9.8/10
Profit MarginProfitability
40.6%10/10

Keeps 41 of every $100 in revenue as profit

Operating MarginProfitability
41.7%10/10

Strong operational efficiency at 41.7%

Altman Z-ScoreHealth
8.5610/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
21.8%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

CGC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$467.04M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-33.6%2/10

ROE of -33.6% — below average capital efficiency

Revenue GrowthGrowth
-0.3%2/10

Revenue declined 0.3%

UTHR3 concerns · Avg: 2.7/10
PEG RatioValuation
2.244/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.6%2/10

Revenue declined 1.6%

EPS GrowthGrowth
-12.2%2/10

Earnings declined 12.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : CGC

The strongest argument for CGC centers on Price/Book.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.

Bear Case : CGC

The primary concerns for CGC are EPS Growth, Market Cap, Return on Equity.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

CGC profiles as a turnaround stock while UTHR is a declining play — different risk/reward profiles.

CGC carries more volatility with a beta of 2.41 — expect wider price swings.

CGC is growing revenue faster at -0.3% — sustainability is the question.

UTHR generates stronger free cash flow (363M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (57/100 vs 30/100), backed by strong 40.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Canopy Growth Corp

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. The company is headquartered in Smiths Falls, Canada.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?